Briefing: STAT+: Eli Lilly and the ‘societal obligation’ of GLP-1s

Eli Lilly has articulated the importance of GLP-1 medications, which are increasingly recognized for their role in managing metabolic conditions.

The company's emphasis on these treatments reflects a broader commitment to addressing public health challenges through innovative therapies.

In related news, Merck's acquisition of Terns Pharma is noted, indicating ongoing consolidation and investment in the biotech sector.